Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Liquid Biopsy Market by Cancer Type, Circulating Biomarkers, Product & End Users - Global Forecast to 2022 - Research and Markets

Research and Markets
Posted on: 03 Oct 17

The "Liquid Biopsy Market by Cancer Type (Lung, Breast, Colorectal, Prostate), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA), Product (Instruments, Assay Kits), End User (Reference Laboratory) - Global Forecast to 2022" report has been added to Research and Markets' offering.

The global liquid biopsy market is projected to reach USD 2,047.9 Million by 2022 from USD 715.7 Million in 2017, at a CAGR of 23.4%.

Factors such as increasing prevalence of cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancements to augment market revenues, rising emphasis on personalized medicine in clinical practice, and increased funding for liquid biopsy R&D are driving the growth of the market.

The number of companies offering liquid biopsy devices is increasing, globally. Major market players are focusing on strengthening their product offerings, mergers and acquisitions, and geographic presence by entering into contracts and agreements with other established players in the market. For instance, in January 2017, Bio-Rad Laboratories, Inc. (US) entered into a definitive agreement with RainDance Technologies, Inc. (US) to acquire the latter. The acquisition will result in Bio-Rad's expansion into next-generation sequencing applications.

The report analyzes the liquid biopsy market by product, circulating biomarker, clinical application, application, end user, and region. On the basis of product and service, the market is segmented into assay kits, instruments, and services. The assay kits segment is expected to account for the largest share of the global market in 2017. Factors such as the increasing demand for liquid biopsy tests, increasing applications of liquid biopsies, and the need for reliable and specific assays are expected to drive the market in the coming years.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Liquid Biopsy Market, By Product And Service

7 Liquid Biopsy Market, By Circulating Biomarker

8 Liquid Biopsy Market, By Clinical Application

9 Liquid Biopsy Market, By Application

10 Liquid Biopsy Market, By End User

11 Liquid Biopsy Market, By Region

12 Competitive Landscape

13 Company Profiles

  • Biocept, Inc.
  • Bio-Rad Laboratories, Inc.
  • Genomic Health, Inc.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Mdxhealth Sa
  • Menarini-Silicon Biosystems
  • Myriad Genetics, Inc
  • Qiagen N.V.
  • Raindance Technologies, Inc
  • Roche Diagnostics
  • Thermo Fisher Scientific Inc.
  • Trovagene, Inc.

For more information about this report visit https://www.researchandmarkets.com/research/gxnl8z/liquid_biopsy

View source version on businesswire.com: http://www.businesswire.com/news/home/20171002005913/en/

Business Wire
www.businesswire.com

Last updated on: 03/10/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.